Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 06/17/2025 at 15:00, 7 months 20 days ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRIEF

published on 06/11/2025 at 16:05, 7 months 26 days ago

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 06/11/2025 at 16:05, 7 months 26 days ago

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
PRESS RELEASE

published on 06/11/2025 at 16:00, 7 months 26 days ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 7 months 27 days ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
BRIEF

published on 06/09/2025 at 22:20, 7 months 27 days ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
PRESS RELEASE

published on 06/09/2025 at 22:15, 7 months 27 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population
BRIEF

published on 06/09/2025 at 15:05, 7 months 28 days ago

Jaguar Health Discusses Crofelemer Pathway with FDA

Crofelemer FDA Approval Orphan Drug Designation Metastatic Breast Cancer Expanded Access Program
BRIEF

published on 06/09/2025 at 15:05, 7 months 28 days ago

Jaguar Health discute du protocole Crofelemer avec la FDA

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Cancer Du Sein Métastatique Programme D'accès Élargi
PRESS RELEASE

published on 06/09/2025 at 15:00, 7 months 28 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting

Napo Pharmaceuticals Crofelemer Jaguar Health Cancer Therapy Metastatic Breast Cancer

Accesswire

Published on 02/07/2026 at 01:00, 20 hours 47 minutes ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 22 hours 37 minutes ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 23 hours 46 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 6 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 8 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 46 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 5 hours 11 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 5 hours 26 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 2 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 3 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 1 day 3 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 3 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 5 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 5 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 13 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE